SUMMARY
Activation of EP2 receptors by prostaglandin E2 (PGE 2 ) promotes brain inflammation in neurodegenerative diseases but the responsible pathways are unclear. EP2 receptors couple to Gαs and increase cAMP, which associates with protein kinase A (PKA) and cAMP-regulated guanine nucleotide exchange factors (Epac). Here, we studied EP2 function and its signaling pathways in rat microglia in their resting state or undergoing classical activation in vitro following treatment with low concentrations of lipopolysaccharide and interferon-γ. Real-time PCR showed that PGE 2 had no effect on expression of CXCL10, TGF-β1 and IL-11, exacerbated the rapid upregulation of mRNAs encoding COX-2, iNOS, IL-6 and IL-1β, but blunted the production of mRNAs encoding TNF-α, IL-10, CCL3 and CCL4. These effects were mimicked fully by the EP2 agonist butaprost but only weakly by the EP1/EP3 agonist 17-phenyltrinor PGE 2 or the EP4 agonist CAY10598, not at all by the EP3/EP1 agonist sulprostone, and confirmed by protein measurements of COX-2, IL-6, IL-10 and TNF-α. In resting microglia butaprost induced cAMP formation and altered the mRNA expression of inflammatory mediators, but protein expression was unchanged. The PKA inhibitor H89 had little or no effect on inflammatory mediators modulated by EP2, whereas the Epac activator 8-pCPT-2'-O-Me-cAMP-AM mimicked all butaprost effects. These results indicate that EP2 activation plays a complex immune-regulatory role during classical activation of microglia, and that Epac pathways are prominent in this role.
As the tissue macrophages of the central nervous system (CNS), microglia play the key role in the brain's innate immunity system, actively monitoring their environment and reacting quickly to local damage with a nuanced set of "activation responses" (1) . About 10-20% of the total glial cells in the brain are microglia (2) . Under resting conditions they are characterized by a small cell body with fine, ramified processes and low expression of surface antigens (3) . In response to brain injury, ischemia or inflammatory stimuli, microglia rapidly transform into an activated phenotype associated with proliferation, migration to the site of injury, elaboration of a host of both neurotoxic and neurotrophic cytokines and chemokines, and phagocytosis of cellular debris (1, 4, 5) . Activated microglia have enlarged cell bodies attached to a few short, thick processes and play key roles in neuroinflammation and neurodegenerative diseases.
Cyclooxygenase-2 (COX-2, PTGS2) is dramatically upregulated in neurons following injury or seizures that engage the N-methyl-Daspartate system (6, 7) . Both COX-2 and PGE 2 are functionally implicated in brain inflammation. Cytosolic prostaglandin E synthase (cPGES) and microsomal PGES-2 (mPGES-2) are constitutively expressed, whereas microsomal PGES-1 (mPGES-1) is inducible and is often coupled to COX-2 leading to PGE 2 synthesis during inflammation (8-10). PGE 2 activates four different G protein-coupled receptors designated EP1, EP2, EP3 and EP4 (11). Previous studies and our real-time PCR results show only EP1, EP2 and EP4 are expressed by rat microglia (12-14) and together they influence microglial function in complex ways. For example, PGE 2 decreases microglial expression of IL-12 and B7-2 (necessary for antigen presentation) produced by high concentrations of lipopolysaccharide (LPS) and interferon-γ (IFN-γ) (15,16). Moreover, PGE 2 is reported to downregulate iNOS, IL-1β and TNF-α expression in LPS-activated microglia (14,17), and at the same time to upregulate the expression of anti-inflammatory IL-10 (18). Based on these findings, PGE 2 could appear to both interfere with inflammatory pathways and promote anti-inflammatory pathways in activated microglial cells.
EP2 receptors (PTGER2) are seventransmembrane receptors that couple to Gαs and increase cAMP concentration. Previously, cAMP signaling had only been known to signal through PKA (19). Epac1 (RAPGEF3) and Epac2 (RAPGEF4) have been recently identified as alternative cAMP mediators that regulate physiological processes either alone and/or in concert with PKA (20,21). Recent evidence based on EP2 gene ablation indicates that activation of EP2 receptors might promote inflammation in several mouse models of neurodegenerative diseases including Alzheimer's disease (22), Parkinson's disease (23), and amyotrophic lateral sclerosis (24). EP2 gene ablation also abrogates LPS-induced, microglial-mediated neurotoxicity, as well as induction of COX-2 and iNOS (25). A selective and brain-permeant EP2 antagonist has recently been shown to blunt inflammation in a pilocarpine epilepsy model (26). Based on these results, we asked whether modulation of innate immunity by EP2 activation in microglia proceeds through PKA or Epac? Our findings establish an immunomodulatory role for EP2 that proceeds largely through Epac pathways. ) and EP2 antagonist TG4-155 were synthesized in our laboratory (27-29). All plasticware and reagents were endotoxin-free.
EXPERIMENTAL PROCEDURES

Animals and Microglial Cell Culture -Pregnant
Sprague-Dawley Rats were from Charles River Laboratories. Primary microglia were prepared from the cortex of newborn (p1-3) SpragueDawley rats as previously described (30,31). In brief, cortical tissue was carefully freed from blood vessels and meninges, triturated, and washed. Cortical cells were cultured in DMEM/10% FBS with penicillin/streptomycin (P/S) plus 2 ng/ml GMCSF for 11-21 d (media changed every 2-3 d). Microglia were separated from the underlying astrocytic monolayer by gentle agitation and spun down (300g for 10 min). The cell pellet was resuspended in DMEM/10% FBS with P/S plus 0.2 ng/ml GMCSF and plated on primaria culture dishes or plates (BD Biosciences). Non-adherent cells were removed after 30-60 min by changing the medium, then adherent microglia were incubated for 24 hour in culture medium before being serum starved in MSFM plus 0.2 ng/ml GMCSF for 24 hr. Such cultures consist of >95% Ox42-positive microglia (29).
RNA Isolation, Reverse Transcription and
Quantitative Real-Time PCR -RNA isolation (including on-column DNase digestion) and cDNA synthesis were done by using PureLink RNA Mini Kit and Superscript Reverse Transcriptase ІІ from Invitrogen. Then simplex quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the iQ™5 Multicolor real-time PCR System (BIO-RAD). iQ™ SYBR Green SuperMix Kit was used to amplify transcripts of interest and endogenous controls HPRT1, β-actin and GAPDH. Normalization of qRT-PCR data was performed by subtracting the geometric average of these three internal control genes from the measured cycle threshold of each gene of interest (32). The following components were combined per 20 μl reaction volume: cDNA, 10 μl SYBR Green SuperMix, 400 nM mouse forward primer and reverse primer. Cycling conditions were 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Melting curve analysis was used to verify single species PCR product. Fluorescent data were acquired at the 60°C step. All experiments had a "no template" negative control and most primers used were intronspanning (Supplementary Table 1 ). Data were analyzed by a relative quantification method as previously described (33,34).
TR-FRET cAMP assay -cAMP was measured with a homogeneous TR-FRET method (Cisbio Bioassays). The assay is based on generation of a strong FRET signal upon the interaction of two molecules: an anti-cAMP antibody coupled to a FRET donor (Cryptate), and cAMP coupled to a FRET acceptor (d2). Endogenous cAMP produced by cells competes with labeled cAMP for binding to the cAMP antibody, and thus reduces the FRET signal. Briefly, microglia were seeded into 384-well plates in 30 µl complete medium (4,000 cells/well) and grown overnight. The medium was thoroughly withdrawn and 10 µl Hank's Buffered Salt Solution (HBSS) (Hyclone) plus 20 µM rolipram was added into the wells to block phosphodiesterase. The cells were incubated at room temperature for 30 min and then treated with vehicle or TG4-155 for 30 min before addition of butaprost for 2 hours. The cells were lysed in 10 µl lysis buffer containing the FRET acceptor cAMP-d2 and 1 min later another 10 µl lysis buffer with anti-cAMPCryptate was added. After 60-90 min incubation at room temperature, the TR-FRET signal was detected by an Envision 2103 Multi-label Plate Reader (PerkinElmer) with a laser excitation at 337 nm and dual emissions at 665 nm and 590 nm for d2 and Cryptate, respectively. The FRET signal is expressed as: F665/F590 × 10 4 .
ELISA and western blot -After being seeded and then serum starved, rat microglia received various treatments for 24 h. Then supernatants were collected and frozen at -80°C. The levels of IL-6 and TNF-α were measured with commercial ELISA kits from R&D Systems. The cells were lysed in RIPA buffer with proteinase and phosphatase inhibitors (Thermo Scientific). Lysate was cleared by centrifugation at 14,000g for 15 min and stored at -80°C. The protein level of COX-2 was measured by western blot. The polyclonal COX-2 antibody was from Cayman Chemical and polyclonal iNOS antibody from Abcam.
Statistical Analysis -Statistical evaluation was carried out using PRISM software (GraphPad, San Diego, CA). Multiple comparisons were made using one-way ANOVA with Bonferroni post-test. Data are presented as mean ± S.E.M. and statistical significance was assumed if p<0.05.
RESULTS
EP2 activation modulates expression of inflammatory mediators in rat microglia -
Resting state microglia were stimulated with 100 nM or 1 µM PGE 2 , 200 nM or 2 µM butaprost, or 10 ng/mL each LPS and IFN-γ for 2 hours, then the levels of mRNAs encoding inflammation-related genes were measured by RT-PCR. We selected 14 inflammatory modulators to study. COX-2, iNOS, the cytokines IL-1β, IL-6, IL-10, IL-11 and TNF-α, and the chemokines CXCL10, CCL3 and CCL4, are all important inflammatory mediators in the brain. Ablation of COX-2 in forebrain neurons dampens brain inflammation after status epilepticus in part by reducing the induction of CCL3, CCL4, CXCL10, IL-11 and TNF-α (6). For the remaining proteins, EP1 and EP2 are important prostanoid receptors that can be activated by PGE 2 , TGF-β1 appears to be neuroprotective in ischemic brain and stroke and BDNF supports neuronal survival after injury and encourages the growth and differentiation of new neurons and synapses. Following treatment the genes fell into four groups (Fig. 1) , those that were induced by all three agents (COX-2, iNOS, IL-6, IL-1β), those induced by LPS/IFN-γ but suppressed by PGE 2 and butaprost (TNF-α, IL-10 (see Fig. 3 ), CCL3, CCL4), one induced only by LPS/IFN-γ (CXCL10), and those little or unaffected by any of the three agents (EP1, EP2, TGF-β1, BDNF, IL-11). Based on these results we selected COX-2, iNOS, IL-1β, IL-6, IL-10, TNF-α, CCL3 and CCL4 for additional study.
In rat microglia stimulated with 10 ng/mL each of LPS and IFN-γ for 2 hours to trigger classical activation (35), mRNA levels encoding all eight of these inflammatory mediators were increased as described above. Pretreatment with 1 µM PGE 2 for 30 min dose-dependently potentiated the induction of COX-2, iNOS, IL-1β and IL-6 mRNA and suppressed the LPS/IFN-γ-induced expression of TNF-α, CCL3 and CCL4 mRNA. PGE 2 had little or no effect on expression of CXCL10 and EP2 mRNA in activated microglia (not shown). The EP2 agonist butaprost (2 µM) mimicked each PGE 2 effect in microglia undergoing classical activation (Fig. 2&4 ). Agonists selective for the other PGE 2 receptors were then used to determine whether other PGE 2 receptors modulate microglial activation. 17-Phenyltrinor PGE 2 activates EP1 and EP3 (36) and increases intracellular [Ca2+] in rat astrocytes with EC50 = 69 nM (SJ Myers and R Dingledine, unpublished). Sulprostone activates EP3 receptors with EC50 <1 nM (36) and has a weaker effect on EP1. Finally, CAY10598 is a selective EP4 agonist (37) with EC50 = 18 pM for elevating cAMP in human EP4-expressing HEK293 cells, whereas 10 µM CAY10598 elicits only 10% of the maximum cAMP signal in microglia produced by PGE 2 (Y Quan and R Dingledine, not shown). At saturating concentrations, 17-phenyltrinor PGE 2 (2 µM) and CAY10598 (100 nM) were much less effective than butaprost in modulating expression of these inflammatory mediators, and sulprostone (2 µM) had no effect (Fig. 2) . These data taken together indicate that EP2 receptors contribute strongly to the modulatory effects of PGE 2 in classically-activated rat microglia, with EP1 and EP4 playing a minor role if any. The two other Gαs-coupled prostanoid receptors, DP1 and IP, appear to play no role in microglia because saturating concentrations of BW245C (1 µM) and iloprost (10 nM) had no effect on cAMP levels (not shown). We also tested the effect of forskolin, a direct adenylate cyclase activator, on expression of these inflammatory mediators in classically-activated microglia. The EC50 of forskolin is 10 µM for elevating cAMP in primary rat microglia (not shown). A subsaturating concentration of forskolin (50 µM) mimicked the effect of butaprost and PGE 2 on the three EP2-induced inflammatory mediators, and partially mimicked their effect on the EP2-suppressed cytokines (Fig. 2) . The lower efficacy of forskolin on the down-regulated cytokines suggests involvement of G-proteins other than Gαs, or perhaps a β-arrestin signaling pathway.
ELISA and Western blot were then performed to determine whether secreted cytokine protein levels were also altered by EP2 activation. Induction of COX-2 protein by butaprost required LPS/IFN-γ treatment (Fig.  3B ). The EP2 agonist butaprost (200 nM) increased IL-6 secretion in rat microglia stimulated with 10 ng/mL LPS/IFN-γ for 24 hours ( Fig. 3C ) but decreased TNF-α secretion (Fig. 3D) , and the EP2 inhibitor TG4-155 (1 µM, Fig. 3A ) prevented these effects. EP2 activation by butaprost in the absence of LPS/IFN-γ, however, had no effect on 24 hr inflammatory protein expression ( Fig. 3B-D ) even though 2 hr of butaprost treatment alone altered mRNA expression of these cytokines in resting microglia (Fig. 1 ). Similar effects were obtained when cytokine and COX-2 protein levels were measured 8 hr after stimulation with butaprost (not shown), making it unlikely that a transient protein induction escaped notice. The EP2 antagonist did not alter inflammatory mediator levels beyond that of LPS/IFN-γ treatment itself (Fig. 3C&D ), suggesting that classical activation of microglia does not require EP2 receptor activation. Similarly, LPS/IFN-γ (10 ng/ml for 72 hr) induced IL-10 mRNA and protein levels, and butaprost (200 nM) opposed IL-10 induction (Fig. 3E) . These results indicate that EP2 activation rapidly modulates the mRNA expression of inflammatory mediators in both resting and activated microglia, but these effects are translated to changes in protein expression only in microglia undergoing classical activation.
EP2 receptor pharmacology in rat microgliaThe results described above indicate that, of the four PGE 2 receptors, EP2 is the most prominent modulator of inflammatory mediators in resting or activated microglia. To explore EP2 pharmacology in microglia, we examined the effects of an EP2 receptor antagonist (28) and allosteric potentiator (27) .
Rat primary microglia cultures were preincubated with vehicle or 1 µM of the competitive EP2 antagonist TG4-155 (28) for 20 min, followed by addition of EP2 agonist butaprost at different concentrations. After 5 min microglia were stimulated with 10 ng/mL LPS/IFN-γ for 2 hours, and mRNA was then isolated to measure inflammatory gene expression. The expression of iNOS is more sensitive to LPS/IFN-γ so 1 ng/mL LPS/IFN-γ was used for iNOS. Butaprost dose-dependently potentiated the induction of COX-2, iNOS, IL-1β and IL-6 mRNA expression in classicallyactivated microglia and TG4-155 at 1 µM completely blocked these effects (Fig. 4A) . Additionally, butaprost dose-dependently downregulated TNF-α, CCL3 and CCL4 mRNA expression in classically-activated microglia, but TG4-155 at 1 µM appeared to be less potent at inhibiting butaprost's inhibitory effects (Fig.  4B) . Thus, TG4-155 antagonized the effect of EP2 receptors in classically-activated microglia although it appeared to be more potent against the EP2-inducible mediators than the EP2-downregulated mediators suggesting that different conformations of the EP2 receptor might exist.
The thiophene carboxylate, TG3-95-1 (Fig.  5C , inset, named compound 1 in ref 27) was previously reported as an allosteric potentiator of recombinant human EP2 receptors expressed in C6 glioma cells (27). Similar to its mode of action on human EP2 receptors, TG3-95-1 also increased the potency of both PGE 2 and butaprost 2.1-fold on endogenous EP2 receptors in rat microglia (Fig. 5A&B) . This molecule was then used to determine whether potentiation of EP2 affected the expression of inflammatory gene mRNA in rat microglia stimulated with 10 ng/mL LPS/IFN-γ for 2 hours. TG3-95-1 at 20 µM potentiated both the induction of COX-2, iNOS, IL-1β (not shown) and IL-6 mRNA expression by 100 nM butaprost (Fig. 5D ) and the reduced expression of TNF-α, CCL3 and CCL4 mRNA (Fig. 5E ). The EC50 of TG3-95-1 for potentiating COX-2 induction was 7.9 µM (Fig. 5C ), consistent with its potency on cAMP production (27). In the absence of butaprost the EP2 potentiator had no effect, reinforcing the conclusion that microglial activation does not require EP2.
To determine whether classical activation alters the potency of EP2 agonists or antagonist, we preincubated rat primary microglia cultures with vehicle or 100 nM TG4-155 for 30 min, followed by addition of butaprost or PGE 2 for 2 hours. Cellular cAMP levels were evaluated by a TR-FRET assay. Butaprost and PGE 2 dosedependently increased cAMP level in rat primary microglia, with similar potencies in the resting or activated state (Fig. 6A-D) . Likewise, 100 nM or 0.3 µM TG4-155 produced a parallel shift to the right in the concentration-response curves of both agonists, with the magnitude of the shift being similar in both resting and activated state conditions. The estimated Schild K B is 14 nM against butaprost and 10 nM against PGE 2 , which is about 5-fold lower potency than measured in C6G cells overexpressing human EP2 receptors (28). These data, together with pharmacological results described above, demonstrate that PGE2 and butaprost up to at least 1 µM act entirely on EP2 receptors in both resting and activated rat microglia, that butaprost's weaker action on EP3 receptors (38) does not come into play under our conditions, and that the only source of cAMP in PGE 2 -stimulated microglia is EP2.
Epac contributes to EP2 signaling in rat microglia -Cyclic AMP produced by EP2 activation can bind to the regulatory subunit of PKA, causing dissociation of this subunit from the enzyme thus activating the catalytic subunit, or bind to a regulatory subunit of Epac with similar effect (21). To determine which of these pathways mediates the effect of EP2 activation on inflammatory mediators, we studied the effects of the PKA inhibitor H89 at 5 µM and Epac activator 8-pCPT-2'-O-Me-cAMP-AM up to 10 µM. These concentrations were chosen as being selective for PKA and Epac, respectively (39) (40) (41) (42) .
As shown in Fig. 7A , the Epac agonist had a qualitatively similar effect on the mRNA levels of seven inflammatory mediators in resting microglia as had been previously shown for PGE 2 and butaprost (cf. Fig. 1 ). H89 (5 µM) exerted little or no inhibition of the effect of butaprost (Fig. 7B) . Likewise, in microglia undergoing classical activation, H89 (5 µM) failed to block the modulation by butaprost of the mRNA expression of these inflammatory mediators (Fig. 8A) .
We next turned attention to the effect of an Epac agonist (10 µM), which was found to mimic butaprost's effect in microglia undergoing activation (Fig. 8B) . H89 exerted similar small effects on the response to the Epac agonist (Fig.  7C ) in resting microglia, suggesting that PKA impinges on the Epac pathway. An Epac antagonist has recently been reported (43, 44 ), but we found that this antagonist (10 µM) had no consistent effect on cytokine modulation by the Epac agonist in primary microglia, which precluded its testing against butaprost; we presume the antagonist has poor cell penetration in microglia under our conditions. These data are consistent with the notion that cAMPactivated Epac, not PKA, mediates much of EP2 receptor's effect on the mRNA expression of inflammatory genes in both resting and classically-activated microglia.
DISCUSSION
We show that in classically-activated or resting state microglia, EP2 receptor activation by PGE 2 or butaprost creates a mixed immune state by exacerbating the rapid induction of proinflammatory COX-2, iNOS, IL-1β and IL-6, but blunting the induction of pro-inflammatory TNF-α and the chemotactic factors CCL3 and CCL4. Selective activation of the other PGE 2 receptors, EP1, EP3 and EP4, has little or no effect on expression of these inflammatory mediators. Based on the effects of a selective PKA antagonist and a selective Epac activator, we conclude that cAMP-activated Epac, not PKA, appears to mediate the effect of EP2 receptors on these inflammatory genes in classically-activated microglia.
COX-2 is an important component of neuroinflammation. In an Alzheimer's disease model, a selective COX-2 inhibitor decreased inflammatory factors and attenuated astrogliosis and neuronal cell loss (45). Inhibition of COX-2 was able to prevent or slow down dopamine neuron degeneration either directly or through inhibition of microglia activation (46) . Likewise, conditional ablation of COX-2 from principal forebrain neurons was neuroprotective and antiinflammatory in a mouse model of epilepsy (6) . iNOS, induced after inflammatory insults in the brain, mediates neurotoxicity because of the oxidative/nitrosative effects produced by NO release and the production of peroxynitrite. In stroke models, excessive glutamate receptor activation induces neurotoxicity partly by iNOS and peroxynitrite production (47). Pharmacological inhibition of iNOS delayed disease onset and extended survival in mutant SOD1 mice, showing iNOS expression in ALS contributed to disease progression (48). IL-6 is a multifunctional cytokine during neuroinflammation in the central nervous system. Mice with IL-6 deficiency were fully resistant to experimental allergic encephalomyelitis (EAE) and IL-6 is proposed to be a therapeutic target for autoimmune diseases (49). However, in traumatic brain injury, mice deficient for IL-6 showed increased oxidative stress, decreased cell survival and delayed wound healing, indicating IL-6 might also be protective (50). Here, we show that PGE 2 and EP2 activation by butaprost exacerbates the induction of COX-2, iNOS, and IL-6 in classically-activated microglia, which should promote inflammation caused by microglial activation.
COX-2 is present in cytosolic vesicle-like structures in macrophages (51), and its protein expression and PGE 2 secretion are low in rat microglia even after treatment with 10 ng/mL LPS/IFN-γ for 24 hours. Butaprost however can increase COX-2 expression at both mRNA and protein levels (Figs. 1-3) , confirming previous results in microglia (25) and suggesting that EP2 activation on microglia by PGE 2 released from any source should produce a self-reinforcing pro-inflammatory effect. The major source of PGE 2 in the early stages of inflammation is likely to be neurons (6), which would promote brain inflammation in part by activating EP2 receptors on nearby microglia.
Based on the effects of EP2 activation on activated microglia, the consequences of EP2 receptor activation at the systems level in the inflamed brain are expected to be complex. Prolonged incubation of rat microglia with LPS/IFN-γ induces delayed expression of the anti-inflammatory cytokine, IL-10, which limits inflammation and promotes survival of neurons and glial cells in the brain (56). Induced IL-10 by LPS/IFN-γ is blunted by EP2 activation. The reduction in IL-10 expression is expected to be a secondary consequence of reduced TNF-α expression, because TNF-α is a strong inducer of IL-10 (52). The cytokine TNF-α plays a multidimensional role in inflammation-induced neuronal damage in brain diseases. TNF-α expression in substantia nigra elicits progressive neurodegeneration, motor symptoms and microglia activation (53), and TNF-α receptor activation enhances microglial phagocytic activity (54). Inhibition of TNF-α prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease (55). Chemokines CCL3 and CCL4 function to attract macrophages from blood, in addition to microglia migrating to the injured site in the brain, and thereby magnify local inflammation in neurodegenerative diseases (56). Our results show that EP2 activation blunts the induction of TNF-α and the chemotactic factors CCL3 and CCL4 in classically-activated microglia, which may inhibit chemotaxis of inflammatory cells in the brain.
Modulation of the immune response by cAMP in monocytes and macrophages had been attributed to PKA and PKA-mediated changes in protein expression and function (57). However, Epac can act as an alternative cAMP mediator in monocytes and macrophages (20). Cytokine and chemokine production in bone marrow-derived dendritic cells involve both Epac1 and PKA (58). It has also been reported that high concentrations of PKA and cell-impermeable Epac agonists play differential roles on the production of cytokines in primary cultured microglia stimulated with a high concentration of endotoxin (59). In our study, the actions of selective concentrations of both H89 (5 µM) and the cell-permeable Epac agonist (10 µM) suggest that cAMP-activated Epac rather than PKA mediates the effect of EP2 receptors on the expression of COX-2, iNOS, and inflammatory cytokines in classically-activated rat microglia.
Our study demonstrates that EP2 activation promotes brain inflammation by exacerbating COX-2, iNOS, IL-1β and IL-6 induction and by opposing IL-10 induction in classically-activated rat microglia. At the same time, PGE 2 and EP2 activation also play a negative feedback role by decreasing TNF-α, CCL3 and CCL4 release to inhibit chemotaxis of inflammatory cells. In conclusion, PGE 2 activated EP2 regulates innate immunity in the central nervous system in a nuanced manner, by promoting many aspects of inflammation while reducing chemotaxis of macrophages and microglia to the inflamed area. Epac signaling pathways are engaged in these EP2 actions and may provide new drug targets for brain inflammation. 
